Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews is Scopus-indexed (Q1, CiteScore 8.6), WoS ESCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by Diabetes India.
Checked against the index lists dated .
ISSN 1871-4021Verify ISSN ↗1878-0334Verify ISSN ↗
Publisher: Diabetes India
Cost to publish: About US$4,450 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Internal Medicine | 28 / 179 | 84th | Q1 |
| Endocrinology, Diabetes and Metabolism | 39 / 250 | 84th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2007–present, best quartile Q1, CiteScore 8.6.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews is Q1 in Internal Medicine (rank 28 of 179) and Q1 in Endocrinology, Diabetes and Metabolism (rank 39 of 250), by CiteScore 2025.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 8.6, which places it in quartile Q1 at the 84th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.170, quartile Q1, with an H-index of 98.
The publisher lists an article processing charge of about US$4,450 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews is published by Diabetes India. Its print ISSN is 1871-4021 and its online ISSN is 1878-0334.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews has an h-index of 121 and a 2-year mean of 5.27 citations per paper (OpenAlex). Its Scopus CiteScore is 8.6, quartile Q1. On 2-year citations it ranks #18 of 172 Scopus journals in Internal Medicine.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews published 119 papers in 2025; its busiest recent year was 2020 with 450. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2025–2026), authors are most often from India (25.5%), China (14.4%) and United Kingdom (8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 7 retracted papers are recorded (2.2 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.